第一单位：
Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute, Ottawa, Canada.
作者：
Tiago A,Mestre [1]
;
Noelle E,Carlozzi [2]
;
Aileen K,Ho [3]
;
Jean-Marc,Burgunder [4]
;
Francis,Walker [5]
;
Aileen M,Davis [6]
;
Monica,Busse [7]
;
Lori,Quinn [8]
;
Filipe B,Rodrigues [9]
;
Cristina,Sampaio [10]
;
Christopher G,Goetz [11]
;
Esther,Cubo [12]
;
Pablo,Martinez-Martin [13]
;
Glenn T,Stebbins [14]
;
Members of the MDS Committee on Rating Scales Development
作者单位：
Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute, Ottawa, Canada.
[1]
Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.
[2]
School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.
[3]
Swiss HD Center, NeuroZentrumSiloah and Department of Neurology, University of Bern, Bern, Switzerland.
[4]
Department of Neurology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.
[5]
Krembil Research Institute, University Health Network and Institute of Health Policy, Management and Evaluation and Rehabilitation Institute, University of Toronto, Toronto, Canada.
[6]
Centre for Trials Research, Cardiff University, Wales, UK.
[7]
Department of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, USA.
[8]
Huntington's Disease Centre, Institute of Neurology, University College London, London, UK.;Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.;Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
[9]
CHDI Foundation/CHDI Management, Princeton, New Jersey, USA.
[10]
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
[11]
Department of Neurology, Hospital Universitário Hermanos Yagüe, Burgos, Spain.
[12]
National Center of Epidemiology and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Carlos III Institute of Health, Madrid, Spain.
[13]
Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
[14]
DOI
10.1002/mds.27317
PMID
29570848
发布时间
2025-05-30
换一批
